biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by bfwon May 21, 2018 10:28am

141 Views

Post# 28059629

RE:Bioasis & WuXi Biologics to Manufacture xB3-001

Excellent choice.

This is is the same group that makes Trogarzo (Ibalizumab) for Taimed/Theratechnologies.

bfw

BioasisUS wrote: We are delighted to announce we have initiated a strategic collaboration with WuXi Biologics to develop and manufacture xB3-001, our lead investigational candidate to treat HER2+ breast cancer brain metastases. To learn more, please visit: https://www.bioasis.us/bioasis-and-wuxi-biologics-announce-initial-strategic-collaboration-for-the-development-and-manufacturing-of-xb3-001-the-companys-lead-investigational-candidate-to-treat-brain-cancer/

Bullboard Posts

Sirios Resource discovers visible gold in Quebec